HerbermanRB, NunnME, HoldenHT and LavrinDH. (1975). Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells. Int J Cancer, 16:230–239.
2.
KiesslingR, KleinE, ProssH and WigzellH. (1975). “Natural” killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell. Eur J Immunol, 5:117–121.
3.
RosenbergSA, LotzeMT, YangJC, TopalianSL, ChangAE, SchwartzentruberDJ, AebersoldP, LeitmanS, LinehanWM, et al. (1993). Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst, 85:622–632.
4.
BurnsLJ, WeisdorfDJ, DeForTE, VesoleDH, RepkaTL, BlazarBR, BurgerSR, Panoskaltsis-MortariA, Keever-TaylorCA, ZhangMJ and MillerJS. (2003). IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial. Bone Marrow Transplant, 32:177–186.
5.
SalagianniM, LekkaE, MoustakiA, IliopoulouEG, BaxevanisCN, PapamichailM and PerezSA. (2011). NK cell adoptive transfer combined with Ontak-mediated regulatory T cell elimination induces effective adaptive antitumor immune responses. J Immunol, 186:3327–3335.
6.
RuggeriL, CapanniM, UrbaniE, PerruccioK, ShlomchikWD, TostiA, PosatiS, RogaiaD, FrassoniF, et al. (2002). Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science, 295:2097–2100.
